JOINT FILING AGREEMENTJoint Filing Agreement • November 28th, 2017 • Stafford John S Iii • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the 10.50% Series E Convertible Preferred Stock, $0.001 par value per share, of Peregrine Pharmaceuticals, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
SETTLEMENT AGREEMENTSettlement Agreement • November 28th, 2017 • Stafford John S Iii • Pharmaceutical preparations • Delaware
